伊普可泮治疗C3肾小球病的疗效与安全性
这项2期开放标签单臂研究纳入27例C3G患者(16例原生病肾、11例移植肾复发),伊普可泮每日两次治疗84天。原生病肾队列UPCR较基线下降45%(P=0.0003),移植肾复发队列C3沉积评分中位数下降2.50(P=0.03),血清C3多数正常化,安全耐受性良好。
要点
- 伊普可泮可显著降低原生病肾C3G患者的UPCR(12周下降45%)
- 移植肾复发C3G患者C3沉积评分中位数下降2.50(P=0.03)
- 多数患者血清C3水平正常化,补体过度激活被抑制
核心结论
- 伊普可泮在原生病肾队列中显著降低UPCR并正常化血清C3,在移植肾复发队列中降低C3沉积评分,安全耐受性良好。
研究设计与样本
- 2期、多中心、开放标签、单臂、非随机研究,纳入27例C3G患者(16例原生病肾队列,11例移植肾复发队列),均完成84天治疗。
主要发现
- 原生病肾队列UPCR从基线至第12周下降45%(P=0.0003)。
- 移植肾复发队列第84天C3沉积评分中位数较基线下降2.50(评分范围0-12,P=0.03)。
- 多数患者血清C3水平正常化,治疗前观察到的补体过度活跃被降低。
- 严重不良事件包括活检后血尿和高钾血症,研究期间无死亡。
临床怎么用
- 对于原生病肾C3G患者,伊普可泮可能作为降低蛋白尿和正常化补体的靶向治疗选择。
- 对于移植肾复发C3G患者,伊普可泮可能减少肾脏C3沉积。
局限性
- 本研究为单臂、开放标签、非随机设计,样本量较小(27例),缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) (measured by complement biomarkers) of iptacopan were assessed in patients with C3G. METHODS: In this phase 2, multicenter, open-label, single-arm, nonrandomized study, adults with biopsy-proven, native kidney C3G (native cohort) and kidney transplant recipients with C3G recurrence (recurrent kidney transplant [KT] cohort) received iptacopan twice daily (bid) for 84 days (days 1-21: 10-100 mg; days 22-84: 200 mg). The primary end point was the urine protein-to-creatinine ratio (UPCR; native cohort) and the change in the C3 deposit score of kidney biopsy (recurrent KT cohort). The complement pathway measures included Wieslab assay, soluble C5b9, and serum C3 levels. RESULTS: A total of 27 patients (16 native cohort and 11 recurrent KT cohort) were enrolled and all completed the study. In the native cohort, UPCR levels decreased by 45% from baseline to week 12 (P = 0.0003). In the recurrent KT cohort, the median C3 deposit score decreased by 2.50 (scale: 0-12) on day 84 versus baseline (P = 0.03). Serum C3 levels were normalized in most patients; complement hyperactivity observed pretreatment was reduced. Severe adverse events (AEs) included post-biopsy hematuria and hyperkalemia. No deaths occurred during the study. CONCLUSION: Iptacopan resulted in statistically significant and clinically important reductions in UPCR and normalization of serum C3 levels in the native cohort and reduced C3 deposit scores in the recurrent KT cohort with favorable safety and tolerability. (ClinicalTrials.gov identifier: NCT03832114).
引用
- Wong E, Nester C, Cavero T, et al. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Kidney Int Rep. 2023. PMID: 38106570. doi:10.1016/j.ekir.2023.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。